Commitments and Contingent Liabilities (Details) ₪ in Thousands, $ in Thousands |
1 Months Ended | 12 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 01, 2020 |
Oct. 31, 2020
USD ($)
|
Apr. 30, 2020
USD ($)
|
Apr. 30, 2020
ILS (₪)
|
Apr. 30, 2019
USD ($)
|
Apr. 30, 2019
ILS (₪)
|
Apr. 30, 2019 |
Dec. 31, 2017
USD ($)
|
Jun. 30, 2015
USD ($)
|
Dec. 31, 2020
USD ($)
|
Dec. 31, 2020
ILS (₪)
|
Dec. 31, 2019
USD ($)
|
Dec. 31, 2019
ILS (₪)
|
Dec. 31, 2018
USD ($)
|
Dec. 31, 2017
USD ($)
|
May 31, 2017
shares
|
|
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Approved budget | $ 1,185 | $ 781 | ||||||||||||||
| Percentage of approved budget | 30.00% | 30.00% | 85.00% | 85.00% | 30.00% | 30.00% | ||||||||||
| Amount of deduction from R&D expense | $ 518 | $ 299 | ||||||||||||||
| Contingent obligation | $ 2,300 | |||||||||||||||
| New application of total budget amount | $ 3,123 | |||||||||||||||
| Other commitments, description | The program was for the period beginning January 2020. | The program was for the period beginning January 2020. | The program is for the period beginning from July 2019 through December 2019. | The program is for the period beginning from July 2019 through December 2019. | ||||||||||||
| Annual license fees | $ 10 | |||||||||||||||
| Amount of liabilities recorded to agreement | 378 | $ 217 | ||||||||||||||
| Research collaboration agreement, description | BiomX Israel entered into a research collaboration agreement with Boehringer Ingelheim International GmbH ("BI") for a collaboration on biomarker discovery for IBD. Under the agreement, BiomX Israel is eligible to receive fees totaling $439 in installments of $50 within 60 days of the Effective date, $100 upon receipt of the BI materials, $150 upon the completion of data processing and $139 upon delivery of the Final Report of observations and Results of the Project (as such terms are defined within the agreement). Unless terminated earlier, this agreement will remain in effect, until one year after the Effective Date or completion of the Project Plan (as defined in the agreement) and submission and approval of the Final Report. As of December 31, 2020, consideration of $150 had been received. | |||||||||||||||
| Contingent obligation to IIA | 2,300 | |||||||||||||||
| Development and commercialization milestones totaling | $ 47,000 | |||||||||||||||
| License Agreement [Member] | ||||||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Approved budget | $ 1,800 | |||||||||||||||
| Annual license fees | $ 10 | |||||||||||||||
| NIS [Member] | ||||||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Approved budget | ₪ 4,221 | 2,700 | $ 2,700 | |||||||||||||
| New application of total budget amount | ₪ | ₪ 10,794 | |||||||||||||||
| 2017 License Agreement [Member] | ||||||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Consideration percentage | 1.00% | |||||||||||||||
| Warrants to purchase ordinary shares | shares | 591,382 | |||||||||||||||
| Additional Application [Member] | ||||||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Approved budget | $ 4,287 | |||||||||||||||
| Percentage of approved budget | 30.00% | 30.00% | ||||||||||||||
| Additional budget | $ 450 | |||||||||||||||
| Commitments and Contingent Liabilities, description | (i) to pay a license issue fee of $20 and annual license fees ranging from $15 to $25 (ii) make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $32,10 and (iii) make tiered royalty payments, in the low single digits based on future revenue. The consolidated financial statements include liabilities with respect to this agreement in the amount of $378 and $217 as of December 31, 2020 and 2019, respectively. | The Company will pay an annual license fee of between $15 and $25 subject to the terms and conditions specified in the agreement. Additionally, the Company is obligated to make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3,210 and royalty payments based on future revenue. As the Company has not yet generated revenue from operations and the achievement of certain milestones is not probable, no provision was included in the consolidated financial statements as of December 31, 2020 and 2019 with respect to the agreement. | ||||||||||||||
| Budget percentage | 30.00% | 30.00% | ||||||||||||||
| Additional Application [Member] | NIS [Member] | ||||||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Approved budget | ₪ | ₪ 15,562 | |||||||||||||||
| Additional budget | ₪ | ₪ 1,634 | |||||||||||||||
| Maximum [Member] | ||||||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Royalties rate | 3.50% | 3.50% | ||||||||||||||
| Annual license fees | $ 25 | |||||||||||||||
| Minimum [Member] | ||||||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Royalties rate | 3.00% | 3.00% | ||||||||||||||
| Annual license fees | $ 15 | |||||||||||||||
| Loan Agreements [Member] | ||||||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Aggregate amount of the remaining potential commitment | $ 83 | 260 | ||||||||||||||
| Patent License Agreement [Member] | ||||||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Annual license fees | $ 25 | |||||||||||||||
| Maximum payments of license maintenance fees | $ 250 | |||||||||||||||
| Royalty payments based on future revenue | 4,700 | |||||||||||||||
| License maintenance fees | $ 250 | |||||||||||||||
| Amount of liabilities recorded to agreement | $ 240 | $ 108 | ||||||||||||||
| Party to a license agreement [Member] | ||||||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||||||
| Other commitments, description | The consolidated financial statements as of December 31, 2020 and 2019 include a liability with respect to this agreement in the amount of $83 and $260, respectively. | The consolidated financial statements as of December 31, 2020 and 2019 include a liability with respect to this agreement in the amount of $83 and $260, respectively. | ||||||||||||||